Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards
- Resource Type
- Review Article
- Source
- In
BBA - Reviews on Cancer November 2022 - Subject
- Language
- ISSN
- 0304-419X